Cheaper drugs help local cancer sufferers
Thirteen more anti-cancer drugs were included in the city’s medical insurance program, bringing more affordable treatment to cancer patients.
Along with the previous four drugs, the 17 drugs all have proven curative effects, but were prohibitively expensive for many patients. Inclusion in the program will reduce their average price by 56.7 percent.
Also, patients will pay substantially less for the previously covered four drugs, Shanghai social security authorities announced over the weekend.
Li Xiangyun, deputy director of the oncology department at Shanghai Chest Hospital, said some of his patients had asked when the inclusion was going to happen, as they had been aware of the forthcoming changes since last month.
“At least five of the 17 are used to treat lung cancer, one of the most prevalent cancers in the city,” said Ye. “Inclusion in public health insurance and lower prices will significantly reduce the burden on patients.”
“Tagrisso, for example, is taken by 7 percent of our lung cancer patients. It used to cost more than 50,000 yuan (US$7,208) per month, but now that has been reduced to around 15,000 yuan and almost 80 percent of that will be covered by public insurance. Patients will save nearly 90 percent.”
Erbitux, another anti-cancer agent on insurance list has a market price of 3,650 yuan, but with the new policy, patients will have to pay only 510.
Shanghai Jiahui International Hospital is the only international hospital covered by the city’s medical insurance. “Including the 17 cancer drugs into public health insurance will greatly reduce patients’ costs,” Ge Feng, president of the hospital, said.
- About Us
- |
- Terms of Use
- |
- RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证:沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证:31120180004
- |
- 网络视听许可证:0909346
- |
- 广播电视节目制作许可证:沪字第354号
- |
- 增值电信业务经营许可证:沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.